We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ECPG:NASDAQEncore Capital Group Inc Analysis

Data as of 2026-06-18 - not real-time

$82.64

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Encore Capital Group trades around $82.6, just below its 20‑day SMA of $80.8 and well above the 200‑day SMA of $60.5, indicating a long‑term uptrend. The MACD histogram is positive (0.23) and the MACD line sits above its signal, a bullish technical signal. RSI at 56 suggests the stock is neither overbought nor oversold, supporting a neutral short‑term bias. Volume is increasing, and the price is holding above the identified support of $77.0 while approaching resistance near $85.3. Fundamentally, the company posts a trailing P/E of 6.4 versus an industry average of 17, and a forward P/E of 6.2, highlighting deep value relative to peers. However, the DCF‑derived fair value of $16.4 is far below the current market price, implying a substantial overvaluation gap of over 400%. The balance sheet shows a debt‑to‑equity ratio of 390%, with total debt exceeding $4 billion, creating leverage concerns. Operating cash flow is positive ($190 M) but free cash flow is negative, reflecting ongoing investment or debt service pressures.
Recent earnings beat, with collections up 20% YoY and EPS of $10.91, plus guidance for 10% EPS growth in 2026, underscores strong operational performance. Insider activity includes a notable sell by SVP Andrew Asch on June 11, which could temper short‑term sentiment. The Fear & Greed Index reads “Extreme Greed,” indicating market enthusiasm that may be detached from fundamentals. Given the low beta (≈0.84) the stock is less volatile than the market, yet 30‑day volatility sits at 27%, suggesting price swings. The overall upside potential per the model is ~34%, but the downside risk is limited by the support level and strong earnings momentum. In this context, the stock presents a mixed picture: attractive earnings and valuation metrics offset by heavy leverage and an inflated market price.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD and rising volume suggest momentum
  • Price near support with room to test resistance
  • Insider sell may create short‑term buying opportunity

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Low P/E relative to industry indicates value potential
  • Strong earnings growth and collection performance
  • Heavy leverage and negative free cash flow limit upside

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • High debt‑to‑equity ratio poses balance‑sheet risk
  • Sustainable operating margins but limited cash generation
  • Market price far above DCF fair value suggesting valuation correction

Key Metrics & Analysis

Financial Health

Revenue Growth21.00%
Profit Margin16.00%
P/E Ratio6.4
ROE31.96%
ROA8.17%
Debt/Equity390.51
P/B Ratio1.7
Op. Cash Flow$190.2M
Free Cash Flow$-229486752
Industry P/E17.1

Technical Analysis

TrendNeutral
RSI56.5
Support$77.02
Resistance$85.35
MA 20$80.79
MA 50$81.11
MA 200$60.49
MACDBullish
VolumeIncreasing
Fear & Greed Index88.5

Valuation

Fair Value$16.38
Target Price$111.00
Upside/Downside34.32%
GradeOvervalued
TypeValue

Risk Assessment

Beta0.84
Volatility27.29%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.